The combination of panobinostat, dexamethasone, and subcutaneous (SC) bortezomib shows promising responses in patients with relapsed or relapsed and refractory multiple myeloma (RRMM), according to the phase II PANORAMA 3* study. Furthermore, SC bortezomib may be preferable to the intravenous (IV) option for reducing toxicity.
Patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) who achieve undetectable minimal residual disease (uMRD) in peripheral blood (PB) and bone marrow (BM) after 12 cycles of first-line treatment with ibrutinib plus venetoclax have similar 1-year disease-free survival (DFS) rates regardless of whether ibrutinib is continued or not, results of the phase II CAPTIVATE study have shown.
In older patients with acute myeloid leukaemia (AML), CC-486 maintenance therapy after intensive chemotherapy (CT) with or without consolidation CT led to improved survival regardless of MRD* status, and preserved baseline QoL status, according to the QUAZAR AML-001 trial presented at ASH 2020.
Treatment with a chimeric antigen receptor (CAR) T-cell therapy yields high response in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) — driving tumour cells down to undetectable levels in close to 80 percent of these patients, according to the ZUMA-5 trial presented at ASH 2020.
Subcutaneous (SC) daratumumab in combination with pomalidomide and dexamethasone (Pd) improves progression-free survival (PFS) and achieves deeper responses vs Pd alone in patients with relapsed/refractory multiple myeloma (R/R MM), results of the phase III APOLLO trial have shown.
Asciminib, a first-in-class investigational treatment specifically targeting the ABL myristoyl pocket (STAMP), has demonstrated superior efficacy and a favourable safety profile vs the BCR-ABL tyrosine kinase inhibitor (TKI) bosutinib in patients with heavily pretreated chronic myeloid leukaemia (CML) in the open-label phase III ASCEMBL trial.